Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Dr. Ronald M. Kurtz M.D.
AddedFeb 15, 2024
UpdatedMay 31, 2026
Dr. Ronald M. Kurtz M.D.

Dr. Ronald M. Kurtz M.D.

CEO, RxSight

CrunchbaseThe Org

Dr. Ronald M. Kurtz M.D.'s Career

RxSight
RxSight

Aliso Viejo, CA, US

CEO· C-Suite · Management
Allegro Ophthalmics
Allegro Ophthalmics

San Juan Capistrano, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Dr. Ronald M. Kurtz M.D.'s Career

RxSight
RxSight
Public$236M2921997Aliso Viejo, CA, US
CEO· C-Suite · Management

Leadership at RxSight

Julie B. AndrewsJulie B. AndrewsBoard Member
Juliet Tammenoms BakkerJuliet Tammenoms BakkerBoard Member
Robert GrubbsRobert GrubbsFounder

Similar to RxSight

ClearsightClearsightAurora, CO, USIntraocular Lensesest. 2012ClearsightAurora, CO, US · est. 2012

ClearSight develops premium intraocular lenses for post-cataract surgery vision enhancement.

Pre-Seed · $1M5
Sight SciencesSight SciencesMenlo Park, CA, USMedical Devicesest. 2011Sight SciencesMenlo Park, CA, US · est. 2011

Sight Sciences, Inc.: A California-based medical device company specializing in vision health.

Public · $173.7M250
ReaLensReaLensAustin, TX, USOphthalmic Devicesest. 2008ReaLensAustin, TX, US · est. 2008

ReaLens, LLC: Innovating in ophthalmic devices with a patented Iris Expander and a unique IntraOcular Lens, enhancing vision for the aging population.

Angel · $100k3k
Atia VisionAtia VisionCampbell, CA, USMedical Devicesest. 2012Atia VisionCampbell, CA, US · est. 2012

Atia Medical Inc: A California-based medical innovation hub providing advanced devices.

Series B · $111.1M29
Allegro Ophthalmics
Allegro Ophthalmics
Private Equity$42.7M112011San Juan Capistrano, CA, US
Board Member· Board

Leadership at Allegro Ophthalmics

John ParkJohn ParkCo-Founder
William LinkWilliam LinkBoard Member
Hampar KarageozianHampar KarageozianBoard Member
Mark LivingstonMark LivingstonBoard Member
Rebecca ColbertRebecca ColbertBoard Member
Vicken KarageozianVicken KarageozianCo-Founder

Similar to Allegro Ophthalmics

Vitreoretinal TechnologiesVitreoretinal TechnologiesIrvine, CA, USDrugs, Pharmaceuticalsest. 1999Vitreoretinal TechnologiesIrvine, CA, US · est. 1999

VitreoRetinal Technologies: A biopharmaceutical firm specializing in ophthalmic drugs and diabetic retinopathy treatment.

Series A · $12M6
Alimera SciencesAlimera SciencesAlpharetta, GA, USPharmaceuticalsest. 2003Alimera SciencesAlpharetta, GA, US · est. 2003

Alimera Sciences Inc.: A biopharmaceutical company specializing in ophthalmic pharmaceuticals.

Public · $304.4M145

Dr. Ronald M. Kurtz M.D.'s Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Dr. Ronald M. Kurtz M.D.

Richard StrobridgeRichard StrobridgeCEO · Rx.HealthGerald E. FinkenGerald E. FinkenCEO · RxE2Paul BadawiPaul BadawiBoard Member · Sight SciencesKeith HartmanKeith HartmanCEO · ContinuumRxSirj GoswamiSirj GoswamiCo-Founder · InsightRX